^
    13d
    Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients. (PubMed, Biomark Res)
    Collectively, the results propose that treatment with LOAd703 and atezolizumab induce an immune phenotype of ICI resistant patients that has previously been reported associative with ICI responsiveness. These results merits further clinical investigation of supplementary LOAd703 treatment to accomplish ICI sensitivity in ICI resistant MM.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD40LG (CD40 ligand)
    |
    Tecentriq (atezolizumab) • delolimogene mupadenorepvec (LOAd703)
    29d
    Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer. (PubMed, Immunooncol Technol)
    LOAd703 was administered every 2 weeks by ultrasound-guided intratumoral injections, combined with a standard-of-care or immune-conditioning gemcitabine-based chemotherapy regimen. A trend of higher interferon-gamma (IFN-γ) plasma levels in the highest LOAd703 dose cohort was observed. The acceptable toxicity associated with LOAd703 and chemotherapy, combined with signs of clinical benefit in poor prognostic cancer patients, warrant further studies.
    Journal
    |
    IFNG (Interferon, gamma) • CD40LG (CD40 ligand)
    |
    gemcitabine • delolimogene mupadenorepvec (LOAd703)
    1m
    NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab (clinicaltrials.gov)
    P2, N=53, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1
    1m
    LOKON001: LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=51, Completed, Lokon Pharma AB | Active, not recruiting --> Completed
    Trial completion
    |
    Tecentriq (atezolizumab) • gemcitabine • albumin-bound paclitaxel • delolimogene mupadenorepvec (LOAd703)
    2ms
    LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial. (PubMed, Nat Commun)
    The small sample size and single arm design limits effect interpretation but the data shows promise for continued clinical investigation. Study registration: NCT04123470.
    P1/2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD40LG (CD40 ligand)
    |
    Tecentriq (atezolizumab) • delolimogene mupadenorepvec (LOAd703)
    2ms
    ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, Orionis Biosciences Inc | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    ORB-011
    2ms
    Converting HR+ Breast Cancer Into an Individualized Vaccine (clinicaltrials.gov)
    P2, N=100, Recruiting, Weill Medical College of Cornell University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Mobista (CDX-301)
    3ms
    1B-22-2: In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, University of Southern California | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)
    3ms
    COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
    P3, N=195, Completed, Canadian Cancer Trials Group | Active, not recruiting --> Completed
    Trial completion
    |
    IMM-101
    4ms
    GEN001-201: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
    P2, N=42, Completed, Genome & Company | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    4ms
    KEYNOTE-D86: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Genome & Company | Recruiting --> Terminated | N=148 --> 10; Sponsor decision
    Enrollment change • Trial termination
    |
    Keytruda (pembrolizumab) • GEN-001
    4ms
    CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Chinese PLA General Hospital | Recruiting --> Active, not recruiting | N=15 --> 9 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Enrollment change • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12
    |
    Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC